BBA
NKTR icon

Baader Bank Aktiengesellschaft’s Nektar Therapeutics NKTR Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-715
Closed -$5.88K – 473
2023
Q1 		$5.88K Buy
+715
New +$21.6K ﹤0.01% 357

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Baader Bank Aktiengesellschaft's NKTR Position: Q2 2023 in Review

Baader Bank Aktiengesellschaft sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 715 shares — an estimated $5.88K sold.

Baader Bank Aktiengesellschaft first reported a position in NKTR in Q1 2023 and held it in 1 quarter. The position peaked at $5.88K in Q1 2023. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • Baader Bank Aktiengesellschaft reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 715 Nektar Therapeutics shares in Q2 2023, an estimated $5.88K.
  • Baader Bank Aktiengesellschaft first reported a position in Nektar Therapeutics in Q1 2023 and held it in 1 quarter.
  • Baader Bank Aktiengesellschaft's Nektar Therapeutics position peaked at $5.88K in Q1 2023.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q2 2023, filed 11 Aug 2023.